Pharmaceutical
Notice Regarding the Results of a Clinical Study in Patients Who Participated in the Phase I Clinical Trial of PPMX-T003 for Polycythemia Vera
Notice Regarding the Results of a Clinical Study in Patients Who Participated in the Phase I Clinical Trial of PPMX-T003 for Polycythemia Vera

About this update from Perseus Proteomics, Inc.
Perseus Proteomics, Inc. (4882) Press ReleaseView Attachment
View stock analysis, news, and events for Perseus Proteomics, Inc.